Wealth Enhancement Advisory Services
ACAD icon

Wealth Enhancement Advisory Services’s Acadia Pharmaceuticals ACAD Stock Holding History

Wealth Enhancement Advisory Services’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$813K Buy
30,998
+830
+3% +$18.3K ﹤0.01% 2240
2026
Q1 		$670K Buy
30,168
+1,947
+7% +$46.5K ﹤0.01% 2103
2025
Q4 		$760K Sell
28,221
-1,506
-5% -$36K ﹤0.01% 2146
2025
Q3 		$640K Buy
29,727
+5,352
+22% +$127K ﹤0.01% 2166
2025
Q2 		$511K Buy
+24,375
New +$453K ﹤0.01% 2210

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Wealth Enhancement Advisory Services's ACAD Position: Q2 2026 in Review

Wealth Enhancement Advisory Services increased its Acadia Pharmaceuticals (ACAD) stake by 2.8% in Q2 2026, buying an estimated $18.3K and bringing the position to 30,998 shares worth $813K. The position accounts for ﹤0.01% of the portfolio, ranked #2240.

Wealth Enhancement Advisory Services first reported a position in ACAD in Q2 2025 and has held it in 5 quarters since. 353 funds tracked by Wall St. Rank hold ACAD as of Q2 2026.

  • Wealth Enhancement Advisory Services held 30,998 shares of Acadia Pharmaceuticals worth $813K as of Q2 2026.
  • Wealth Enhancement Advisory Services bought 830 Acadia Pharmaceuticals shares in Q2 2026, an estimated $18.3K.
  • Acadia Pharmaceuticals made up ﹤0.01% of Wealth Enhancement Advisory Services's portfolio in Q2 2026, its #2240 holding.
  • Wealth Enhancement Advisory Services first reported a position in Acadia Pharmaceuticals in Q2 2025 and has held it in 5 quarters since.
  • 353 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2026.

Based on Wealth Enhancement Advisory Services's 13F filing for Q2 2026, filed 15 Jul 2026.